AAAlexandra Albertsson-Lindblad

Alexandra Albertsson-Lindblad

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alexandra Albertsson-Lindblad has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Mats Jerkeman

    Department of Clinical Sciences Lund, Division of Oncology, Skåne University Hospital, Lund University

    5 shared publications
  • Karin E. Smedby

    Department of Medicine Solna, Clinical Epidemiology Division, Karolinska Institutet

    4 shared publications
  • Sara Ekberg

    Department of Immunology, Genetics and Pathology, Cancer Precision Medicine, Uppsala University

    3 shared publications
  • Ingrid Glimelius

    Department of Immunology, Genetics and Pathology Cancer Precision Medicine Uppsala University Uppsala Sweden

    2 shared publications
  • Ingrid Glimelius

    Department of Immunology, Genetics and Pathology, Cancer Precision Medicine Uppsala University Uppsala Sweden

    2 shared publications
  • Kossi Dovene Abalo

    Laboratoire D’Épidémiologie, Institut de Radioprotection et de Sûreté Nucléaire, Fontenay-aux-Roses Cedex, France

    2 shared publications

Latest Publications

  • Open Access

    Survival in mantle cell lymphoma patients burdened by a second primary malignancy

    by Kossi D. Abalo, Trine Trab, Joachim Baech, Sara Ekberg, Simon Pahnke, Alexandra Albertsson-Lindblad, Karin E. Smedby, Mats Jerkeman, Peter Brown, Thomas Stauffer Larsen, et al.

    Second primary malignancies (SPMs) increasingly affect mantle cell lymphoma (MCL) survivors. In nationwide Danish and Swedish cohorts (2000-2020), we evaluated overall survival among MCL patients with SPMs versus matched non-lymphoma individuals with comparable malignancies and MCL patients without SPMs, respectively. Of 3094 MCL survivors, 19% in Denmark and 15% in Sweden developed an SPM, with a median of three years from MCL diagnosis to first SPM. MCL patients with SPMs had about double the mortality risk compared with non-lymphoma counterparts (pooled HR 2.1, 95% confidence interval (CI) 1.3-3.5), and worse survival than MCL patients without SPMs (pooled HR 1.6, 95% CI 1.4-1.9). In Swedish MCL patients with SPMs, deaths were attributed to subsequent hematologic malignancies (9%), solid cancers (14%), primary MCL (23%), non-cancer causes (11%), with 40% still alive. Development of SPMs in MCL is associated with substantially higher mortality, supporting long-term surveillance and proactive management of late complications.

  • Open Access

    Limited stage mantle cell lymphoma: A real‐world study of primary treatment and prognosis in Sweden 2006–2018

    by Alexandra Albertsson‐Lindblad, Sara Ekberg, Ingrid Glimelius, Fredrik Ellin, Kristina Sonnevi, Catharina Lewerin, Lena Brandefors, Karin E. Smedby, Mats Jerkeman


  • Open Access

    Infections in patients with mantle cell lymphoma

    by Kossi D. Abalo, Sara Ekberg, Therese M. L. Andersson, Simon Pahnke, Alexandra Albertsson‐Lindblad, Karin E. Smedby, Mats Jerkeman, Ingrid Glimelius

    Advancements in treatments have significantly improved the prognosis for mantle cell lymphoma (MCL), and there is a growing population of survivors with an increased susceptibility to infections. We assessed the incidence of infections by clinical characteristics and treatment both before and after MCL diagnosis in Sweden. Patients with a diagnosis of MCL ≥ 18 years between 2007 and 2019 were included, along with up to 10 matched comparators. Infectious disease diagnosis and anti‐infective drug dispensation were identified by the National Patient and the Prescribed Drug Registers, respectively. Patients and comparators were followed from the diagnosis/matching date until death, emigration, or June 30, 2020. Overall, 1559 patients and 15,571 comparators were followed for a median duration of 2.9 and 5 years, respectively. The infection rate among patients was twofold higher, RRadj = 2.14 (2.01–2.27), contrasted to the comparator group. There was a notable rise in infection rates already 4 years before MCL diagnosis, which reached a fourfold increase in the first year after diagnosis and persisted significantly increased for an additional 8 years. Among patients, 69% ( n = 1080) experienced at least one infection during the first year of follow‐up. Influenza, pneumonia, other bacterial infections, urinary tract infections, and acute upper respiratory infections were the most frequent. Notably, MCL remained to be the primary leading cause of death among patients (57%, n = 467/817). Infections as the main cause of death were rare (2.6%, n = 21). Our study highlights the importance of thoroughly assessing infectious morbidity when appraising new treatments. Further investigations are warranted to explore strategies for reducing infectious disease burden.


  • Open Access

    Survival in mantle cell lymphoma after frontline treatment with R-bendamustine, R-CHOP and the Nordic MCL2 regimen – a real world study on patients diagnosed in Sweden 2007-2017

    by Alexandra Albertsson-Lindblad, Thorgerdur Palsdottir, Karin E. Smedby, Caroline E. Weibull, Ingrid Glimelius, Mats Jerkeman


  • Open Access

    Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide

    by Alexandra Albertsson-Lindblad, Catja Freiburghaus, Mats Jerkeman, Sara Ek

    The Bruton’s Tyrosine Kinase (BTK)-inhibitor ibrutinib is highly active in mantle cell lymphoma (MCL) but may inhibit response to anti-CD20 antibody as previously shown in CLL models. We investigated how antibody-dependent cellular cytotoxicity (ADCC) induced by type I/II anti-CD20 antibodies was affected by treatment with ibrutinib in MCL. Furthermore, we investigated if lenalidomide, a potential sensitizer to anti-CD20 treatment, could prevent an inhibitory effect of ibrutinib. Anti-CD20 (rituximab/obinutuzumab) opsonized MCL cell lines were co-cultured with ibrutinib (± lenalidomide)—exposed effector cells, and analyzed for evaluation of cell death. Cell death induced by rituximab was reduced with 75% at 0.5 µM ibrutinib and with 52% at 0.1 µM ibrutinib when induced by obinutuzumab, even by addition of lenalidomide. Moreover, obinutuzumab was associated with higher rate of cell death compared to rituximab. Ibrutinib negatively affects anti-CD20 induced cell death in MCL, not reversed by lenalidomide. Explorations of sequential administration and selective BTK-inhibitors may reveal the optimal combination of novel agents in MCL.